Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands

• Published in: Leukemia research Vol. 50; pp. 37 - 45
• Main Authors: Blommestein, Hedwig M, Groot, Saskia de S, Aarts, Mieke J, Vemer, Pepijn, Vries, Robin De, Abeelen, Annet FMVan, Posthuma, EFMWard, Groot, Carin AUyl-de
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01-11-2016
• Subjects: Antibodies, Monoclonal, Humanized - economics; Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - economics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Chlorambucil; Chlorambucil - therapeutic use; Chronic lymphocytic leukaemia; Cost-Benefit Analysis - methods; Cost-effectiveness; Costs; Hematology, Oncology and Palliative Medicine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - economics; Markov Chains; Netherlands; Obinutuzumab; Ofatumumab; Quality-Adjusted Life Years; Rituximab; Rituximab - therapeutic use; Incremental cost-effectiveness ratio; cost-effectiveness; costs; Obinutuzumab; ICER; Rituximab; Quality-adjusted life-year; Ofatumumab; Chlorambucil; chronic lymphocytic leukaemia; QALY; ITC; Indirect treatment comparison; Costs; Chronic lymphocytic leukaemia; Cost-effectiveness
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/j.leukres.2016.09.005

Highlights • GClb appeared to be a cost-effective treatment strategy compared to RClb and Clb • The ICERs of GClb compared to RClb and Clb were €23,208 and €7,254 per QALY • Indirect treatment comparisons showed favourable ICERs for GClb compared to OClb • The ICERs of GClb compared to OClb varied from €6,556 to €16,180 per QALY